Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAshford Capital Management Inc
Latest Disclosed Ownership9,078 shares
Latest Disclosed Value $ 4,053,690
Ashford Capital Management Inc reports 10.10% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Ashford Capital Management Inc filed a 13F-HR form disclosing ownership of 9,078 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $4,053,690 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 8,245 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 10.10% during the quarter. The current value of the position is $4,056,323 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,078 833 10.10 4,054 8.46 0.5009
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,245 0 0.00 3,738 15.73 0.4164
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,245 538 6.98 3,229 -5.89 0.3597
2025-08-18 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,707 -485 -5.92 3,431 -13.60 0.4031
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,192 273 3.45 3,972 24.56 0.5121
2025-02-18 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,919 0 0.00 3,189 -13.42 0.3762
2024-11-18 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,919 -481 -5.73 3,683 -6.48 0.4597
2024-08-15 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,400 0 0.00 3,937 12.13 0.5316
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,400 -956 -10.22 3,511 -7.75 0.4750
2024-02-15 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,356 3,299 54.47 3,807 80.72 0.5100
2023-11-15 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,057 -420 -6.48 2,106 -7.59 0.3101
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,477 -106 -1.61 2,279 9.88 0.3185
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,583 7 0.11 2,074 9.22 0.3105
2023-02-15 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,576 -167 -2.48 1,899 -2.72 0.2945
2022-11-16 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,743 -2,462 -26.75 1,952 -24.75 0.2977
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,205 -8 -0.09 2,594 7.90 0.3686
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,213 -544 -5.58 2,404 12.18 0.2589
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,757 1,568 19.15 2,143 44.31 0.2137
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,189 1,183 16.89 1,485 5.10 0.1349
2021-08-26 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,006 -420 -5.66 1,413 -11.47 0.1274
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,426 1,717 30.08 1,596 18.31 0.1491
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,709 219 3.99 1,349 -9.71 0.1305
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,490 -361 -6.17 1,494 -12.07 0.1776
2020-08-17 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,851 863 17.30 1,699 43.13 0.2200
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,988 228 4.79 1,187 13.92 0.2094
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,760 2 0.04 1,042 29.28 0.1392
2019-11-15 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,758 961 25.31 806 15.80 0.1165
2019-08-15 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,797 0 0.00 696 -0.29 0.0932
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,797 -383 -9.16 698 0.72 0.1019
2019-02-15 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,180 0 0.00 693 -14.02 0.1134
2018-11-15 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,180 4,180 806 0.0973
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.